Author ' s response to reviews Title : Gemcitabine based combination chemotherapy in advanced pancreatic cancer

Author ' s response to reviews Title : Gemcitabine versus gemcitabine based combination chemotherapy in advanced pancreatic cancer

S-1 and gemcitabine as an outpatient-based regimen in patients with advanced or metastatic pancreatic cancer.

OBJECTIVE The standard beneficial chemotherapy proved for patients with pancreatic cancer is a regimen containing gemcitabine. Novel oral fluoropyrimidine, S-1, can be added to gemcitabine to improve the efficacy of chemotherapy and to provide better convenience for patients. We aimed to evaluate the efficacy and safety of S-1 plus gemcitabine combination chemotherapy as a first-line treatment ...

Is There a Standard of Care for the Management of Advanced Pancreatic Cancer?. Highlights from the Gastrointestinal Cancers

Despite advances in our understanding of the molecular and genetic basis of pancreatic cancer, the outcome for this disease remains dismal. Gemcitabine, the standard chemotherapy for pancreatic cancer, offers modest improvement of tumor-related symptoms and marginal advantage of survival. Many chemotherapeutic and targeted agents have been pitted against or combined with gemcitabine in randomiz...

Biweekly gemcitabine with S-1 combination chemotherapy in locally advanced or metastatic pancreatic cancer

Objective: Gemcitabine (GEM)-based combination chemotherapy has been studied to determine whether or not it improves outcomes, but results have generally been disappointing. We retrospectively compared chemotherapy with biweekly GEM plus a novel form of an oral 5-fluorouracil derivative (S1) (GEM+S-1) with GEM alone in locally advanced or metastatic pancreatic cancer. Patients and Methods: We s...

Pancreatic cancer: are we moving forward yet? Highlights from the Gastrointestinal Cancers Symposium. Orlando, FL, USA. January 20th, 2007.

Survival for patients with pancreatic cancer remains abysmal. Standard treatment for resected and locally advanced disease usually consists of 5-fluorouracil (5-FU, either bolus or continuous infusion) and external beam radiation. However, recent studies have shown the role of gemcitabine either used alone or incorporated with 5-FU and external beam radiation in this setting. Gemcitabine and er...